MS Academia: Multiple sclerosis advanced course
|
|
- Barry King
- 5 years ago
- Views:
Transcription
1 13 September London, UK MS Academia: Multiple sclerosis advanced course IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION
2 Robert J. Fox Assessment of treatment response IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION
3 Robert J. Fox, MD Staff Neurologist, Mellen Center for Multiple Sclerosis Vice-Chair for Research, Neurological Institute Professor, Cleveland Clinic Learner College of Medicine Cleveland Clinic, Cleveland, OH, USA Disclosure Dr. Fox has received consulting fees from Actelion, Biogen, Genentech, Mallinckrodt, Novartis, Teva, and Xenoport; and research support from Novartis.
4 Objectives 1. Understand the concept of No Evidence of Disease Activity (NEDA) 2. Apply this NEDA to current MS disease modifying therapies 3. Recognize breakthrough disease activity in clinical practice
5 Nomenclature Disease-Free Status is commonly used, but is discouraged, because we lack methodology to fully evaluate ongoing pathology Disease-Activity Free Status (DAF) is better, but we lack methodology to assert that we have eliminated all disease activity (e.g. triple-dose gadolinium?) No Evident Disease Activity (NEDA) is a reasonable term for this concept. It implies that the neurologist has monitored the patient for disease activity
6 Disease-Free Status in AFFIRM The First Report of the Concept Our aim was to develop composite measures that can be applied in clinical practice and used as a measure of disease remission in clinical studies. Therefore, relapses, progression of disability (sustained for 12 weeks), Gad+ lesions, and new or enlarging T2-hyperintense lesions were taken into account. Havrdova et al. Lancet Neurology 2009;8:254-60
7 Definition from Clinical Trials No new or enlarging T2 lesions No new Gad+ lesions No relapses No confirmed disability worsening Atrophy not included in definition
8 MRI Predictors of Disability Progressive disability at 5 yrs, according to disease activity during first year of IFNβ therapy New MRI lesions are 5-20x more predictive of future disability than relapses and disability progression Prosperini et al, Eur J. Neurol. 2009
9 Definition from Clinical Trials No new or enlarging T2 lesions No new Gad+ lesions No relapses No confirmed disability worsening Atrophy not included in definition
10 Disability Worsening 2 contributors: New inflammation (relapses, new lesions) Degeneration from previous injury Driver of progressive MS Little impact of current therapies on degeneration component Disability worsening may be suboptimal metric for current anti-inflammatory therapies
11 % Disease Activity Free NEDA with Natalizumab No relapse, EDSS progression, or new MRI lesions p < p < p < NEDA at 2 years: Placebo Natalizumab 7% 37% Fold-Increase 5.3 Havrdova et al. Lancet Neurology 2009;8:254-60
12 NEDA with Fingolimod NEDA at 2 years: Placebo Fingolimod 13% 38% Fold-Increase 2.9 Kappos et al., AAN 2011
13 NEDA with Dimethyl Fumarate NEDA at 2 years: Placebo Tecfidera 15% 28% Fold-Increase 1.9 Giovannoni et al., AAN 2012
14 Proportion of Patients (%) NEDA with Teriflunomide No relapses, MRI activity or EDSS worsening 20 14,3 18,4 22,9 NEDA at 2 years: Placebo Teriflunomide 14% 23% Fold-Increase Placebo Teriflunomide 7 mg Teriflunomide 14 mg Freedman MS et al. AAN Annual Mtg, 2012; New Orleans, LA. PD05.007
15 NEDA and MS DMTs 1 year Study Placebo Active Arm Fold natalizumab (AFFIRM) Daclizumab-HYP Pegylated IFNβ1a Q2W years Study Placebo Active Arm Fold natalizumab (AFFIRM) cladribine (CLARITY) Fingolimod (FREEDOMS) BG-12 (DEFINE)
16 Fingolimod vs IFNß-1a IM NEDA at 1 year: IFNß-1a (IM) Fingolimod 34% 46% Fold-Increase 1.4 Khatri et al. AAN 2012
17 Dimethyl fumarate vs glatiramer acetate NEDA at 2 years: BG-12 BID GA 18% 12% Fold-Increase 1.5 (*) Glatiramer Acetate in CONFIRM was an active comparator arm
18 NEDA and MS DMTs Study Duration Comparator Test Drug Fold TRANSFORMS IFNß-1a 30 g (IM) vs fingolimod CARE MS I IFNß-1a 44 g (SC) vs alemtuzumab CARE MS II IFNß-1a 44 g (SC) vs alemtuzumab CONFIRM GA vs BG-12 BID 1 yr yr yr yr
19 NEDA and Improvement A d j u s t e d h a z a r d r a t i o : , 9 5 % C I : ( , ), p - v a l u e :
20 NEDA and Patient Reported Outcomes Bates et al. PS 34- CMSC 2009
21 NEDA in Clinical Practice NEDA from general clinical practice cohort 2-year NEDA: positive predictive value of 78% for no progression at 7y negative predictive value of 41-43% Rotstein et al. JAMA Neurol. 2015;72(2):
22 Definition from Clinical Trials No new or enlarging T2 lesions No new Gad+ lesions No relapses No confirmed disability worsening Atrophy not included in definition
23 Brain Volume and NEDA 1-year brain volume change: -0.86% cut-off yielded sensitivity 71.4% and specificity 65.5% Perez-Miralles et al. Neurol Neuroimmunol Neuroinfl 2015; 21:
24 Brain Volume and NEDA Atrophy estimated from 4 MRIs over 2 years were used to apply cut-offs for atrophy progression Kappos et al, Mult Scler J, 2015
25 Brain Volume and NEDA Caveats: Published studies are from very controlled image acquisitions do not replicate clinical practice Published studies followed patients for 1-2 years. Individual patients have significant biologic variability in atrophy estimates Application of atrophy to routine clinical practice is not ready. Courtesy Kunio Nakamura, PhD, Cleveland Clinic
26 Defining Breakthrough Disease Activity Sormani and De Stefano, Nature Rev Neurol 2013
27 Defining Breakthrough Disease Activity Non-responders behaved similarly to placebo Sormani and De Stefano, Nature Rev Neurol 2013
28 Canadian MS Working Group Recommendations Change treatment for: - 1 High, or - 2 Moderates, or - 3 Lows Limitations: Somewhat cumbersome Doesn t integrate transition to progressive MS Freedman et al, Can J. Neurol Sci, 2013
29 Take-home Message Goal of MS therapy: No evidence of disease activity (NEDA) NEDA is achievable in some patients: Up to 40% NEDA in 2- years with available drugs Disability progression may be confounded by previous injury Treating to Target in the Office: Requires individualized planning with each patient Baseline MRI, follow-up MRI;? New baseline after 3-6 mos? Many modifiers: relapse severity and recovery; lesion characteristics Recognize transition to progressive MS Unresolved issues: Optimal definition, incomplete assessment; integration with treatment risks
MS Academia: Multiple sclerosis advanced course
6 October 2015 - Barcelona, Spain MS Academia: Multiple sclerosis advanced course IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Mark S. Freedman University of Ottawa and the Ottawa
More informationClinical and research application of MRI in diagnosis and monitoring of multiple sclerosis
24-25 February 2016 - Siena, Italy Clinical and research application of MRI in diagnosis and monitoring of multiple sclerosis IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org What
More informationProgress in the field
Progress in the field Eva Havrdová Charles University in Prague 1st Medical Faculty and General University Hospital Disclosures Dr. Havrdová has received consulting fees from Actelion, Biogen Idec, Merck,
More information2013 MS Phenotype Descriptions: Relapsing MS 1
2013 MS Phenotype Descriptions: Relapsing MS 1 Disease-Modifying Therapies? which can be found in its entirety at. Clinically isolated syndrome (CIS) Not Active a Active a,b Relapsing-remitting disease
More informationBenefit/Risk Strategies in Selecting Therapeutic Solutions for MS: HCP and Patient Viewpoints
Benefit/Risk Strategies in Selecting Therapeutic Solutions for MS: HCP and Patient Viewpoints 1 Learning Objectives Review the benefit/risk strategies in selecting therapy for MS patients while assessing
More information1996 vs 2013 MS Phenotype Descriptions of Progressive Disease
Learning Objectives Upon completion, participants should be able to: Describe methods of distinguishing among RRMS, SPMS, and PPMS Incorporate available evidence about emerging and recently approved novel
More informationEAN Amsterdam June 23-27, 2017
EAN 2017 Amsterdam June 23-27, 2017 MS Nowadays-new goals Giancarlo Comi Dept. of Neurology & Institute of Experimental Neurology Università Vita Salute S.Raffaele, Milano European Charcot Foundation Disclosure
More informationA Glimpse at Immunomodulators in MS
A Glimpse at Immunomodulators in MS An Interview with Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC Multiple Sclerosis Research Unit, University of Ottowa, Ottowa Canada Ottawa Hospital Research Institute,
More informationAdvances in the Management of Multiple Sclerosis: A closer look at novel therapies. Disclosures
Advances in the Management of Multiple Sclerosis: A closer look at novel therapies Lily Jung Henson, MD, MMM, FAAN Chief of Neurology Piedmont Healthcare, Atlanta, GA National Association of Managed Care
More informationInnovazione e personalizzazione nella terapia della SM. Rocco Totaro Centro per la Diagnosi e Cura delle Malattie Demielinizzanti L Aquila
Innovazione e personalizzazione nella terapia della SM Rocco Totaro Centro per la Diagnosi e Cura delle Malattie Demielinizzanti L Aquila Which are the objectives of MS treatment? «Historically»
More informationMitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA Disclosures Consultant and Speaker Bureau member for Biogen-Idec, Pfizer, TEVA Neuroscience, Bayer, EMD Serrono, Questcor, Novartis,
More informationMRI in Multiple Sclerosis Features of Cerebral Atrophy with special focus on Multiple Sclerosis. E.W. Radue K. Bendfeldt Till Sprenger
MRI in Multiple Sclerosis Features of Cerebral Atrophy with special focus on Multiple Sclerosis E.W. Radue K. Bendfeldt Till Sprenger Medical Image Analysis Center University Hospital Basel www. miac.ch
More informationLife Long Brain Health and DMT Comparative Effectiveness
Life Long Brain Health and DMT Comparative Effectiveness Timothy Vollmer, MD Professor of Neurology University of Colorado Denver Medical Director- RMMSC and Co-Director Rocky Mountain MS Center at CU
More informationWorkshop II. How to manage highly active MS patients in practice?
Workshop II How to manage highly active MS patients in practice? Gavin Giovannoni Department of Neurology Institute of Cell and Molecular Science Queen Mary University London & Barts and The London NHS
More informationEvidence from bone marrow transplantation
Evidence from bone marrow transplantation Gianluigi Mancardi Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Ospedale Policlinico San Martino, University
More informationUpdate in Multiple Sclerosis
Update in Multiple Sclerosis Kyle Smoot, MD Providence MS Center Portland, OR 1 Disclosures Research funds from Biogen. Consulting fees from Acorda, Biogen, EMDSerono, Genzyme, Novartis, and Teva. 2 Outline
More informationThe Effects of Daclizumab High Yield Process (DAC HYP) on Patient Centered Functional Outcomes: Results From the DECIDE Study
2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers May 27 30, 2015 Indianapolis, IN The Effects of Daclizumab High Yield Process () on Patient Centered Functional Outcomes: Results From
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationDouglas L. Arnold 1,2, Peter A. Calabresi 3, Bernd C. Kieseier 4,5, Shifang Liu 5, Xiaojun You 5, Damian Fiore 5 and Serena Hung 5*
Arnold et al. BMC Neurology (2017) 17:29 DOI 10.1186/s12883-017-0799-0 RESEARCH ARTICLE Open Access Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence
More informationTherapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions
Neurotherapeutics (2017) 14:952 960 DOI 10.1007/s13311-017-0548-5 REVIEW Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions Andrew L. Smith 1 & Jeffrey A. Cohen 1
More informationNeurology and Neurometabolic Unit Department of Neurological and Behavioral Sciences University of Siena Siena, Italy
Nicola De Stefano Neurology and Neurometabolic Unit Department of Neurological and Behavioral Sciences University of Siena Siena, Italy Declared receipt of honoraria or consultation fees from Novartis,
More informationThe invisible facets of MS and everyday challenges clinician s perspective. Mar Tintore
The invisible facets of MS and everyday challenges clinician s perspective Mar Tintore Centre d Esclerosi Múltiple de Catalunya (Cemcat). Department of Neurology/Neuroimmunology Hospital Universitari Vall
More informationORIGINAL CONTRIBUTION. Reliability of Classifying Multiple Sclerosis Disease Activity Using Magnetic Resonance Imaging in a Multiple Sclerosis Clinic
ORIGINAL CONTRIBUTION Reliability of Classifying Multiple Sclerosis Disease Activity Using Magnetic Resonance Imaging in a Multiple Sclerosis Clinic Ebru Erbayat Altay, MD; Elizabeth Fisher, PhD; Stephen
More informationPediatric MS treatments: What do you start with, when do you switch?
Pediatric MS treatments: What do you start with, when do you switch? Tim Lotze, M.D. Associate Professor of Pediatric Neurology Texas Children s Hospital Baylor College of Medicine Disclosures Clinical
More informationLe Hua, MD. Disclosures Teaching and Speaking: Teva Neurosciences, Genzyme, Novartis Advisory Board: Genzyme, EMD Serono
Le Hua, MD Le Hua, MD, is a staff neurologist at Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, NV. She is involved in clinical trials assessing new therapies for the treatment of MS and
More informationHot Topics Multiple Sclerosis. Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018
Hot Topics Multiple Sclerosis Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018 Disclosures Natalie Parks has received compensation from Biogen, EMD Serono, Roche, and Sanofi
More informationDisability Progression After Switching from Natalizumab to Fingolimod or Interferon Beta/Glatiramer Acetate Therapies
Disability Progression After Switching from Natalizumab to Fingolimod or Interferon Beta/Glatiramer Acetate Therapies A NARCOMS Analysis Stacey S. Cofield, PhD; Robert J. Fox, MD; Tuula Tyry, PhD; Amber
More informationCurrent Enrolling Clinical Trials
ASSESS RRMS patients with active disease who are still able to walk. Mariko Kita MD Description of Study/Trial: A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety
More informationClinician s view of Benefit-Risk
Clinician s view of Benefit-Risk Gordon Francis, MD Novartis, Clinical Development Clinician s View of Benefit-Risk: a need for reliable metrics A tale of 3 drugs Natalizumab MS Crohn s Disease Fingolimod
More informationAchieving New Treatment Goals in Multiple Sclerosis Strategies for Initial Treatment Selection and Patient Engagement. Dayton, OH
A CME/CE-certified Symposium held in conjunction with the 2018 Annual Meeting of the CMSC Jointly provided by: In collaboration with: This program was supported by an educational grant from Sanofi Genzyme.
More informationActivity presentations are considered intellectual property.
Activity presentations are considered intellectual property. Activity presentations are considered intellectual property and are for viewing purposes only. No content should be copied or reproduced in
More informationMultiple Sclerosis Diagnosis And Therapy
Multiple Sclerosis Diagnosis And Therapy 1 / 6 2 / 6 3 / 6 Multiple Sclerosis Diagnosis And Therapy Treatment. There is no cure for multiple sclerosis. Treatment typically focuses on speeding recovery
More informationNeuroimaging and Other Biomarkers. MRI for Diagnosis, Prognosis and Treatment Decisions in MS
Neuroimaging and Other Biomarkers MRI for Diagnosis, Prognosis and Treatment Decisions in MS Eric Klawiter, MD MSc Massachusetts General Hospital May 30, 2014 Disclosures and Funding Disclosures: Consulting
More informationBruce Cree, MD, PhD, MCR. BG-12 Has Shown Nrf2 Pathway. Activation. DEFINE (BG-12/Dimethyl Fumarate) : Study Design
MS Therapies Update 212 Bruce Cree, MD, PhD, MCR BG12 Alemtuzumab Daclizumab BAF312 Erythropoetin Outline Fingolimod IFN β-1a Natalizumab Oral solumedrol Duloxetine O BG-12 Has Shown Nrf2 Pathway O OH
More informationAPPENDIX D SASKATCHEWAN MS DRUGS PROGRAM
APPENDIX D SASKATCHEWAN MS DRUGS PROGRAM PROCEDURE FOR OBTAINING COVERAGE OF MS DRUGS UNDER THE DRUG PLAN Requests are initiated by a physician. The patient and physician complete the application form
More informationPresented at the Annual Congress of ECTRIMS, October 11, 2018, Berlin, Germany
Final Results of a Placebo Controlled, Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mab), in Patients with Relapsing Forms of Multiple Sclerosis
More informationShutting Down MS: New Insights on Induction, Escalation, Oral Agents, and Monitoring
Activity presentations are considered intellectual property. These slides may not be published or posted online without permission from Vindico Medical Education (cme@vindicocme.com). Please be respectful
More informationTreating MS. New medicines, strong evidence, better practice? September 2015
Treating MS New medicines, strong evidence, better practice? September 2015 1 A Treatment Revolution for RRMS Over the past 20 years there has been a revolution in treatments for relapsing remitting MS
More informationTreating MS patients earlier in the disease progression may affect long-term outcomes 1-4
Treating MS patients earlier in the disease progression may affect long-term outcomes 1-4 TIME DISEASE ONSET EARLY TREATMENT NATURAL COURSE OF MS LATER TREATMENT DISABILITY INCREASE The disease activity
More informationCarolyn Taylor, M.D. Swedish Neuroscience Center
Carolyn Taylor, M.D. Swedish Neuroscience Center When should disease modifying therapy be discontinued in MS? Should we be using aggressive treatments earlier in the MS disease course and reserving the
More informationMULTIPLE SCLEROSIS IN Managing the complexity of multiple sclerosis. Olga Ciccarelli and Alan Thompson
MULTIPLE SCLEROSIS IN 2015 Managing the complexity of multiple sclerosis Olga Ciccarelli and Alan Thompson The application of imaging biomarkers has provided new insights into the mechanisms of damage
More informationMedication Policy Manual. Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January
More informationEfficacy convenience of MS treatments. Xavier Montalban Department of Neurology-Neuroimmunology. ECF Baveno 2013
Efficacy convenience of MS treatments Xavier Montalban Department of Neurology-Neuroimmunology ECF Baveno 2013 Disclaimer Dr. Montalban has received speaking honoraria and travel expenses for scientific
More informationBiologics and Beyond: Treatment of Multiple Sclerosis. Rita Jebrin, PharmD, BCPS
Biologics and Beyond: Treatment of Multiple Sclerosis Rita Jebrin, PharmD, BCPS Disclosure Information Biologics and Beyond: Treatment of Multiple Sclerosis Rita Jebrin, PharmD, BCPS I have no financial
More informationIs it time to target no evident disease activity (NEDA) in multiple sclerosis?
Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Giovannoni, G; Turner, B; Gnanapavan, S; Offiah, C; Schmierer, K; Marta, M Licensed with a Creative Commons Attribution Non-Commercial
More informationProgram Highlights. A multidisciplinary AAN working group identified areas for improvement in the diagnosis and management of patients with MS
CasePerspectives: Illuminating Dark Pathways in Complex MS Cases Program Highlights Stephen Krieger, MD Associate Professor of Neurology Corinne Goldsmith Dickinson Center for MS Director, Neurology Residency
More informationCSF Axonal Injury Markers
CSF Axonal Injury Markers Gavin Giovannoni Barts and The London Disclosures Professor Giovannoni has received personal compensation for participating on Advisory Boards in relation to clinical trial design,
More informationMRI in MS: the radiologist perspective
MS Preceptorship - Updating Knowledge in Multiple Sclerosis - June, 1-3 2010 Barcelona MRI in MS: the radiologist perspective Àlex Rovira Unidad de Resonancia Magnética Servicio de Radiología Hospital
More informationProgressive Multiple Sclerosis
Progressive Multiple Sclerosis Definitions, Clinical Course and Emerging Therapies M. Mateo Paz Soldán, MD, PhD Neurology Service, VA Salt Lake City HCS Assistant Professor of Neurology, University of
More informationABSTRACT ORIGINAL RESEARCH. Ralf Gold. Gavin Giovannoni. J. Theodore Phillips. Robert J. Fox. Annie Zhang. Jing L. Marantz
Neurol Ther (2016) 5:45 57 DOI 10.1007/s40120-016-0042-8 ORIGINAL RESEARCH Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing Remitting Multiple Sclerosis:
More informationHorizon Scanning Centre July Ocrelizumab for relapsing-remitting multiple sclerosis SUMMARY NIHR HSC ID: 3711
Horizon Scanning Centre July 2014 Ocrelizumab for relapsing-remitting multiple sclerosis SUMMARY NIHR HSC ID: 3711 This briefing is based on information available at the time of research and a limited
More informationUpdate on DMTs in Multiple Sclerosis
Update on DMTs in Multiple Sclerosis John R. Corboy, MD Professor, Neurology 3/4/2017 Disclosures Honoraria Board Member Research Editorial Prime CME NMSS Med Day; Novartis; Biogen; PCORI; NMSS Editor,
More informationMULTIPLE SCLEROSIS - REVIEW AND UPDATE
MULTIPLE SCLEROSIS - REVIEW AND UPDATE Luka Vlahovic, MD Neuroimmunology/Multiple Sclerosis Creighton University Medical Center MS is primary demyelinating disease of the central nervous system. MS is
More informationLong-term results of the first line DMT depend on the presence of minimal MS activity during first years of therapy: data of 15 years observation
Boyko Multiple Sclerosis and Demyelinating Disorders (2016) 1:14 DOI 10.1186/s40893-016-0015-x Multiple Sclerosis and Demyelinating Disorders RESEARCH ARTICLE Open Access Long-term results of the first
More informationNovartis real-world data at AAN confirms benefit of Gilenya on four key measures of disease activity in relapsing MS
Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Novartis real-world data at AAN confirms
More informationPer Soelberg Sørensen
Per Soelberg Sørensen Danish Multiple Sclerosis Center Department of Neurology Rigshospitalet, University of Copenhagen Copenhagen, Denmark Declared receipt personal compensation for serving on scientific
More informationSwitching from natalizumab to fingolimod: an observational study
Acta Neurol Scand 2013: 128: e6 e10 DOI: 10.1111/ane.12082 Ó 2013 John Wiley & Sons A/S ACTA NEUROLOGICA SCANDINAVICA Clinical Commentary Switching from natalizumab to fingolimod: an observational study
More informationWhen choosing among treatments for
Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate J. Theodore Phillips, MD, PhD; Krzysztof Selmaj, MD, PhD;
More informationAnisha Keshavan. Roland Henry, PhD. Proportion of Patients (%) Rituximab 2000mg (n=66) Placebo (n=35)
Two Faces of Multiple Sclerosis February 8, 217 5 T H A N N U A L R E C E N T A D V A N C E S I N N E U R O L O G Y B CELL THERAPY FOR MULTIPLE SCLEROSIS: A NEW DAY? Inflammation Relapsing MS Anisha Keshavan
More informationUpdates to the Alberta Drug Benefit List. Effective August 1, 2018
Updates to the Alberta Drug Benefit List Effective August 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780) 498-8370
More informationNatalizumab (Tysabri; Biogen Idec, Inc, Elan Pharmaceuticals,
n report n Recommendations for the Selection, Treatment, and Management of Patients Utilizing Natalizumab Therapy for Multiple Sclerosis John Foley, MD Abstract Natalizumab is an integrin receptor antagonist
More informationHorizon Scanning Centre July Daclizumab High Yield Process for relapsing forms of multiple sclerosis first or second line
Horizon Scanning Centre July 2014 Daclizumab High Yield Process for relapsing forms of multiple sclerosis first or second line SUMMARY NIHR HSC ID: 2635 This briefing is based on information available
More informationDiagnosis and Monitoring of Patients With Multiple Sclerosis
Diagnosis and Monitoring of Patients With Multiple Sclerosis From the 2017 guidelines to newest modalities. By Edward Fox, MD, PhD; Esther Melamed, MD, PhD; and Elliot Frohman, MD, PhD Multiple sclerosis
More informationRisk attitudes and risk perceptions in individuals with multiple sclerosis
Original Article Risk attitudes and risk perceptions in individuals with multiple sclerosis Bonnie I Glanz, Emily Greeke, Allison LaRussa, Fiona Stuart, David J Rintell, Tanuja Chitnis and Brian C Healy
More informationFor HCPs Brain Health: Time Matters
For HCPs Brain Health: Time Matters Gavin Giovannoni Barts and The London Disclosures Professor Giovannoni has received personal compensation for participating on Advisory Boards in relation to clinical
More informationEfficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials
RESEARCH ARTICLE Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials Vissia Viglietta 1, David Miller 2, Amit Bar-Or 3, J.
More informationCME/CNE ARTICLE 2017 SERIES NUMBER
CME/CNE ARTICLE 2017 SERIES NUMBER 3 Spinal Cord as an Adjunct to Brain Magnetic Resonance Imaging in Defining No Evidence of Disease Activity in Multiple Sclerosis Subhash Tummala, MD; Tarun Singhal,
More informationPATIENT INFORMATION: Patient Surname First Name Middle Initial Sex Date of Birth Alberta Personal Health Number M / F Year Month Day
Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 6 PATIENT INFORMATION: Patient Surname First Name Middle Initial Sex Date of Birth Alberta Personal Health Number M
More informationCurrent & Emerging Treatment & Novel Strategies in the Management of MS
Current & Emerging Treatment & Novel Strategies in the Management of MS Dr Shiv Saidha, MD, MRCPI Assistant Professor of Neurology, Johns Hopkins University School of Medicine Disclosures Dr. Saidha receives
More informationCircle Yes or No Y N. [If no, skip to question 8.] 2. Has the patient been compliant with therapy as verified by the prescriber?
06/01/2016 Prior Authorization AETA BETTER HEALTH OF MICHIGA (MEDICAID) Tecfidera (MI88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationMultiple Sclerosis: Emerging Therapies
Multiple Sclerosis: Emerging Therapies Bruce Cree, MD, PhD, MCR Conflicts of Interest EMD Serono: Grant support ovartis: Adviser, Clinical Trial Participant What are the Future Considerations for MS Therapies?
More informationConsortium of Multiple Sclerosis Centers 2015 Abstract #3485
Alemtuzumab (ALE) Improves Disability After Switch from Other Disease Modifying Therapies in a High Disability, Treatment Refractory Relapsing MS Cohort Consortium of Multiple Sclerosis Centers 2015 Abstract
More informationCurrent and Emerging Therapies
Current and Emerging Therapies for Multiple Sclerosis William Meador, MD University of Alabama at Birmingham School of Medicine, Birmingham, Alabama Abstract Over the past 21 years, nine treatments for
More informationReal-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis
Open Access pissn 1738-6586 / eissn 2005-5013 / J Clin Neurol 2018 ORIGINAL ARTICLE Real-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis Su-Hyun
More informationTechnology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta441
Daclizumab for treating relapsing remitting multiple sclerosis Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta441 NICE 2017. All rights reserved. Subject to Notice of rights
More informationMedscape: What do you see as the main clinical implications of your results?
http://www.medscape.com/px/viewindex/more?bucket=columns§ionid=2011 Treatment Optimization for Multiple Sclerosis: An Expert Interview With Mark Freedman, MD Posted 11/10/2004 Editor's Note: Multiple
More informationSwitching or Discontinuing Disease-Modifying Therapies for Multiple Sclerosis Aaron E. Miller, MD, FAAN
Review Article Switching or Discontinuing Disease-Modifying Therapies for Multiple Sclerosis Aaron E. Miller, MD, FAAN ABSTRACT Purpose of Review: This article reviews the reasons for discontinuation or
More informationLong-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing remitting multiple sclerosis: the CLARITY Extension study
753365TAN0010.1177/1756285617753365Therapeutic Advances in Neurological DisordersG Comi, S CooK research-article2018 Therapeutic Advances in Neurological Disorders Original Research Long-term effects of
More informationTreatment Algorithm for Multiple Sclerosis Disease-modifying Therapies
Treatment Algorithm for Multiple Sclerosis Disease-modifying Therapies NHS England Reference: 170079ALG Date Published: 4 September 2018 Gateway reference: 07603 Treatment Algorithm for Multiple Sclerosis
More informationPharmacotherapy Update Multiple Sclerosis
Pharmacotherapy Update Multiple Sclerosis Yolande Hanssens SIG Leader Medicine Information Hamad Medical Corporation Pharmacy Department - Clinical Service Unit Doha - Qatar Heidelberg/October 2017 Pharmacotherapy
More informationHow do I choose the correct disease-modifying treatment?
Teaching Course 1 How do I choose the correct disease-modifying treatment? R.J. Fox (Cleveland, US) E. Havrdová (Prague, CZ) Chairs: 1 Starting an MS disease modifying therapy: individualised treatment
More informationMellen Center Approaches: Natalizumab
Cleveland Clinic Mellen Center for Multiple Sclerosis Treatment and Research 216.444.8600 Mellen Center Approaches: Natalizumab Who should be considered for Natalizumab therapy? In the phase II and phase
More informationUpdates to the Alberta Human Services Drug Benefit Supplement
Updates to the Alberta Human Services Drug Benefit Supplement Effective December 9, 2013 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone
More informationAscertaining the Role of the Primary Care Clinician in the Recognition and Management of Patients With Multiple Sclerosis in the Modern Era
Ascertaining the Role of the Primary Care Clinician in the Recognition and Management of Patients With Multiple Sclerosis in the Modern Era Edward J. Fox, MD, PhD MS Clinic of Central Texas Central Texas
More informationTechnology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta493
Cladribine tablets for treating relapsing remitting multiple sclerosis Technology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta493 NICE 2018. All rights reserved. Subject to Notice
More informationClinical Policy: Mitoxantrone (Novantrone) Reference Number: CP.PHAR.258 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Novantrone) Reference Number: CP.PHAR.258 Effective Date: 08.01.16 Last Review Date: 05.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationOptimizing Immunomodulatory Therapy with Interferon Beta in Patients with Multiple Sclerosis A Prospective Study
Optimizing Immunomodulatory Therapy with Interferon Beta in Patients with Multiple Sclerosis A Prospective Study Said Masri, MD; Andreas Blodau, MD; Norbert Zessack, PhD; Michael Lang, MD; for the High
More informationStarting Disease-modifying Therapy (DMT) Recommendations
AAN Summary of Practice Guideline for Clinicians Practice Guideline: Disease-modifying Therapies for Adults with Multiple Sclerosis This is a summary of the American Academy of Neurology (AAN) publication,
More informationTreatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis(review)
Cochrane Database of Systematic Reviews Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis(review) Filippini G, Del Giovane C, Clerico M, Beiki
More informationMultiple Sclerosis Update
Multiple Sclerosis Update Amanda Stahnke, PharmD, BCACP University of Missouri-Kansas City School of Pharmacy Kansas City Veterans Affairs Honor Annex Kelsey Morris, PharmD University of Kansas Health-System
More informationCHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island
#CHAIR2014 7TH ANNUAL CHAIR SUMMIT Master Class for Neuroscience Professional Development September 11 13, 2014 Westin Tampa Harbour Island Sponsored by #CHAIR2014 Use of MRI in Clinical Decision- Making
More informationEline Huisman, 1 Katerina Papadimitropoulou, 1 James Jarrett, 2 Matthew Bending, 2 Zoe Firth, 2 Felicity Allen, 3 Nick Adlard 3
To cite: Huisman E, Papadimitropoulou K, Jarrett J, et al. Systematic literature review and network meta-analysis in highly active relapsing remitting multiple sclerosis and rapidly evolving severe multiple
More informationMultiple sclerosis (MS) is a chronic immunemediated. Antidepressant Drug Treatment in Association with Multiple Sclerosis Disease-Modifying Therapy
Systematic Review of Tools for Anxiety in MS COMORBIDITY IN MS Antidepressant Drug Treatment in Association with Multiple Sclerosis Disease-Modifying Therapy Using Explorys in the MS Population Matthew
More informationHealth-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs
CNS Drugs (2017) 31:585 602 DOI 10.1007/s40263-017-0444-x REVIEW ARTICLE Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs Peter Joseph Jongen 1,2 Published
More informationMS Trust Comments on the ACD
MS Trust Comments on the ACD Name xxxxxxxxxxx Role other Other role xxxxxxxxxxxxxxxxxx Location England Conflict no Notes Comments on individual sections of the ACD: Section 1 The MS Trust maintains that
More informationChoices. Disease modifying treatments. Read me
Choices Disease modifying treatments Read me Disease modifying treatments Disease modifying therapies (DMTs) are medications which modify the course of multiple sclerosis (MS) and are designed to reduce
More informationDaclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
The new england journal of medicine Original Article versus Interferon Beta-1a in Relapsing Multiple Sclerosis L. Kappos, H. Wiendl, K. Selmaj, D.L. Arnold, E. Havrdova, A. Boyko, M. Kaufman, J. Rose,
More informationPatient 1: 31-Year-Old Female. Fingolimod treatment
Cell Counts (10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Lymphocyte Pharmacodynamics and Safety of Use in Patients Previously
More informationMultiple Sclerosis: The Safety Efficacy Balance and Preventing Neurodegeneration
Multiple Sclerosis: The Safety Efficacy Balance and Preventing Neurodegeneration Introduction The treatment landscape for multiple sclerosis (MS) has seen extensive growth over the last several decades.
More information